Nuklearmedizin-nuclear Medicine最新文献

{"title":"Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0","authors":"F. Kind, A. C. Eder, C. A. Jilg, P. E. Hartrampf, P. T. Meyer, J. Ruf, K. Michalski","doi":"10.1055/s-0043-1766156","DOIUrl":"https://doi.org/10.1055/s-0043-1766156","url":null,"abstract":"Ziel/Aim Quantitative assessments of positron emission tomography/computer tomography targeting the prostate specific membrane antigen (PSMA PET/CT) are promising for the evaluation of response to [Lu-177]PSMA radioligand therapy (PSMA RLT). Both the updated PSMA PET/CT consensus statement (CS) [1] as well as the recently introduced Response Evaluation Criteria In PSMA-PET/CT (RECIP 1.0) [2], strongly emphasize the change in whole-body tumor volume as a major response criterion. PSMATV50 [3], based on a 50% threshold of the lesional maximum standardized uptake value, appears to be a promising parameter for whole-body tumor volume determination. In the present study PSMATV50 was used for both CS and RECIP 1.0 in order to assess their predictive value for overall survival (OS).","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136002535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors","authors":"Q. X. Liu, H. R. Kulkarni, T. Z. Zhao, C. Schuchardt, X. Chen, Z. H. Zhu, J. Zhang, R. P. Baum","doi":"10.1055/s-0043-1766219","DOIUrl":"https://doi.org/10.1055/s-0043-1766219","url":null,"abstract":"Ziel/Aim Metastatic medullary thyroid carcinoma (MTC) is often has a rapid disease progression and poor prognosis with few therapeutic options available. Peptide Receptor Radionuclide Therapy (PRRT) has demonstrated success in the management of gastroenteropancreatic neuroendocrine tumors and has also been used to treat MTC. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC, to determine survival and potential predictors of survival.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voxel-based dosimetry predicts hepatotoxicity in hepatocellular carcinoma patients undergoing radioembolization with 90Y glass microspheres","authors":"M. Watanabe, H. Grafe, J. Theysohn, B. Schaarschmidt, J. Ludwig, L. Jochheim, M. Jeschke, H. Schmidt, W. P. Fendler, A. Moraitis, K. Herrmann, K. L. Pomykala, M. Weber","doi":"10.1055/s-0043-1766312","DOIUrl":"https://doi.org/10.1055/s-0043-1766312","url":null,"abstract":"Ziel/Aim Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance doses for healthy liver tissue (HLT) are assessed by calculating the mean whole-liver normal tissue dose (WLNT), which neglects non-uniform dose distribution. Thus, we analyzed whether voxel-based dosimetry could be more accurate in predicting hepatotoxicity in HCC patients undergoing radioembolization.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalia","authors":"","doi":"10.1055/a-2040-9488","DOIUrl":"https://doi.org/10.1055/a-2040-9488","url":null,"abstract":"PD Dr. Christoph Rischpler ([Abb. 1]) ist seit Januar 2023 neuer Ärztlicher Direktor der Klinik für Nuklearmedizin im Klinikum Stuttgart. Er war zuletzt kommissarischer Leiter der Nuklearmedizin im Evangelischen Bethesda-Krankenhaus zu Duisburg sowie W2-Professor für nuklearkardiologische Bildgebung am Universitätsklinikum Essen. Sein Medizinstudium hat der Facharzt für Nuklearmedizin unter anderem in München, San Francisco und Sydney absolviert. Am Klinikum Stuttgart möchte Christoph Rischpler die nuklearkardiologische Bildgebung und neue Therapien wie die PSMA-Radioligandentherapie und die Peptid-Radiorezeptortherapie stärken. Dazu strebt er die Zertifizierung der Klinik als nuklearkardiologisches Zentrum an.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136121604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bestimmung der Aktivitätskonzentration von Nuklidgemischen von I-131 und Lu-177m/Lu-177 im Abwasser einer nuklearmedizinischen Therapiestation. Methode 1","authors":"D. Kupitz, E. Einspänner, H. Wissel, A. Hohn, M. C. Kreissl, O. S. Grosser","doi":"10.1055/s-0043-1766289","DOIUrl":"https://doi.org/10.1055/s-0043-1766289","url":null,"abstract":"Ziel/Aim Für die Freigabe radioaktiver Stoffe lt. StrlSchV ist die Quantifizierung der vorliegenden Nuklide erforderlich. Hierfür wurden zwei Methoden für die Analyse von Nuklidgemischen (I-131 und Lu-177m/Lu-177) untersucht. In der hier vorgestellten Methode werden die Energiespektren einer Probe zu zwei Zeitpunkten gemessen und die spezifischen Aktivitätskonzentrationen (AKs) der vorhandenen Nuklide ermittelt. Ein typisches Nutzungsszenario ist die Freigabe von Abwässern aus einer Abwasserschutzanlage.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"149 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioiodine ablation of thyroid remnants in patients with Graves’ orbitopathy","authors":"M. Weber, J. Koenen, N. Bechrakis, M. Stöhr, K. Herrmann, W. P. Fendler, A. Eckstein, M. Oeverhaus","doi":"10.1055/s-0043-1766224","DOIUrl":"https://doi.org/10.1055/s-0043-1766224","url":null,"abstract":"Ziel/Aim To assess response following ablation of thyroid remnants (ATR) with radioactive iodine therapy (RAIT) in patients with unstable Graves’ orbitopathy (GO) after (subtotal) thyroidectomy.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135419772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis.","authors":"Michael Cordes,&nbsp;Theresa Ida Götz,&nbsp;Torsten Kuwert,&nbsp;Christian Schmidkonz","doi":"10.1055/a-1972-9372","DOIUrl":"https://doi.org/10.1055/a-1972-9372","url":null,"abstract":"<p><strong>Aim: </strong>Our aim was to test the assertion that in terms of rate or severity level, adverse events (AEs) after fine-needle aspiration biopsies (FNABs) of thyroid nodules are unfazed by daily low-dose (100 mg) aspirin (acetylsalicylic acid, ASA) intake.</p><p><strong>Methods: </strong>We selected 268 patients for study, grouped as ASA-treated (P_ASA, n=78) or control (P_Ctrl, n=190) subjects. Controls received no antithrombotic medication. AE rates and severities were then analyzed based on patient- and nodule-related factors. We also compared group rates of non-diagnostic cytology results.</p><p><strong>Results: </strong>AEs arising after FNABs (P_ASA, 5%; P_Ctrl, 8%) did not differ significantly by group in rate (<i>p</i>=0.4873) or severity level (<i>p</i>=0.3399). All were classifiable as minor incidents, none warranting any intervention.</p><p><strong>Conclusions: </strong>The data from the present study suggest, AEs after FNABs of thyroid nodules seldom occur and qualify as minor incidents. Such procedures may be safely conducted in patients taking daily low-dose ASA. There is no evidence to support preemptive therapeutic withdrawal.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"34-37"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT].","authors":"Ali Afshar-Oromieh,&nbsp;Matthias Eiber,&nbsp;Wolfgang Fendler,&nbsp;Matthias Schmidt,&nbsp;Kambiz Rahbar,&nbsp;Hojjat Ahmadzadehfar,&nbsp;Lale Umutlu,&nbsp;Boris Hadaschik,&nbsp;Oliver W Hakenberg,&nbsp;Paolo Fornara,&nbsp;Jens Kurth,&nbsp;O Neels,&nbsp;Hans-Jürgen Wester,&nbsp;Markus Schwaiger,&nbsp;Klaus Kopka,&nbsp;Uwe Haberkorn,&nbsp;Ken Herrmann,&nbsp;Bernd J Krause","doi":"10.1055/a-1984-8167","DOIUrl":"https://doi.org/10.1055/a-1984-8167","url":null,"abstract":"<p><p>PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. ⁶⁸Ga-PSMA-11, ⁶⁸Ga-PSMA-I&T, ⁶⁸Ga-PSMA-617, ¹⁸F-DCFBC, ¹⁸F-DCFPyL, ¹⁸F-PSMA-1007, ¹⁸F-rhPSMA-7 and ¹⁸F-JK-PSMA-7). However, an official approval is available only for ⁶⁸Ga-PSMA-11 (approved by the US FDA in 2020) and ¹⁸F-DCFPyL (approved by the US FDA in 2021).Recommendations for acquisition times vary from 1-2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder.PSMA-ligands are physiologically taken up in multiple normal organs. For some ¹⁸F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"5-19"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of bone marrow biopsy and fluorodeoxyglucose-positron emission tomography for the assessment of bone marrow infiltration in children with Hodgkin's lymphoma.","authors":"Esra Arslantaş,&nbsp;Ali Ayçiçek,&nbsp;Ferhan Akıcı,&nbsp;Selvinaz Özkara,&nbsp;Burçak Yılmaz,&nbsp;Nihal Özdemir,&nbsp;Cengiz Bayram","doi":"10.1055/a-1972-9292","DOIUrl":"https://doi.org/10.1055/a-1972-9292","url":null,"abstract":"<p><strong>Purpose: </strong>To compare bone marrow biopsy (BMB) with [18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (PET/CT) imaging in the demonstration of bone marrow involvement in children with Hodgkin's Lymphoma (HL) and to investigate the effectiveness of PET/CT imaging and thus the necessity for BMB at staging.</p><p><strong>Methods: </strong>Pediatric patients with HL, who underwent both bilateral iliac BMB and PET/CT imaging at disease staging were retrospectively analyzed. In determining bone marrow involvement (BMinv), BMB and/or first/follow-up PET/CT imaging were eligible for review.</p><p><strong>Results: </strong>Fifty-six patients were included. BMinv was detected by PET/CT imaging in 6/56 (10.7%), whereas the proportion was 3/56 (5.3%) in BMB specimens. Bone marrow biopsies and PET/CT images were concordant in 53/56 (94.6%) patients with BMB specimens missing three cases of BMinv detected by PET/CT. When diagnostic accuracy was calculated, sensitivity, specificity, positive predictive value and negative predictive values for PET/CT were 100%, 100%, 100%, 100%, respectively, and the same values for BMB were 50%, 100%, 100%, 94.3%, respectively.</p><p><strong>Conclusions: </strong>The results of PET/CT and BMB for staging of pediatric HL patients were compatible, and PET/CT imaging was found to provide high diagnostic performance in determining BMinv. In keeping with earlier research, the current study showed that BMB may not be necessary in every patient at staging, and should be reserved for cases where PET/CT is inconclusive.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"20-26"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of activity kinetics in breast milk and calculation of the resulting effective radiation dose after 99mTc-MIBI scintigraphy of a breastfeeding women.","authors":"Christian Happel,&nbsp;Daniel Gröner,&nbsp;Wolfgang Tilman Kranert,&nbsp;Frank Grünwald","doi":"10.1055/a-1937-9466","DOIUrl":"https://doi.org/10.1055/a-1937-9466","url":null,"abstract":"<p><strong>Introduction: </strong>In breastfeeding women, the indication for scintigraphic imaging is strongly restricted due to potential transition of the radiopharmaceutical to the child via breast milk. The potential activity uptake of the breastfed child depends on the chemical compound of the radio pharmaceutical as well as biokinetics and metabolism in the maternal body.</p><p><strong>Methods: </strong>In the presented case ^99mTc-MIBI scintigraphy was performed in a breastfeeding woman with sonographically suspicious thyroid nodules. Breastfeeding was interrupted for 30 hours and the breast milk during this period was collected and analysed to determine the excreted activity and the potentially resulting dose to the breastfed child.</p><p><strong>Results: </strong>Activity concentration in the first breast milk sample (1.83 hours after administration of 500 MBq ^99mTc-MIBI) was 380 Bq/mL, resulting in an absolute activity of 50 kBq for a sample size of 132 mL. Subsequently activity concentration decreased to 6 Bq/mL (29.8 hours p.i.). The calculated effective half-life of the secretion of ^99mTc-MIBI via breast milk was 4.7 hours. The potentially resulting effective dose for the breastfed child was 13.4 µSv (ICRP80: dose coefficient: 0.13 mSv/MBq for ^99mTc).</p><p><strong>Conclusion: </strong>Time activity curve showed a rapid decrease of the ^99mTc-MIBI activity secreted to the breast milk. More than 90 % of the total secreted activity is attributable to the first 12 hours after administration. Therefore, an interruption of breastfeeding of 24 hours seems to be adequate.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"45-46"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9234281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}